Last reviewed: June 18, 2026
Last updated: June 18, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide has transformed weight loss treatment, but not everyone achieves the same results. Clinical data shows that approximately 35% of people lose less than 5% of body weight on GLP-1 therapy, while others exceed 15% weight loss. Understanding why requires looking beyond the medication itself and into your unique genetic blueprint.
Why Semaglutide Response Varies Between Individuals
Semaglutide works by mimicking glucagon-like peptide-1 (GLP-1), a hormone that controls hunger signals and blood sugar. However, your genes determine how sensitive your GLP-1 receptors are to this medication. Someone with a highly responsive GLP1R gene variant may feel full after smaller doses, while another person with a less sensitive variant might need higher doses or see slower appetite suppression. This genetic variability is a primary reason why two patients on identical semaglutide doses experience different hunger levels and weight loss trajectories.
Beyond receptor sensitivity, your body's ability to metabolize semaglutide also differs. Genetic factors influence how quickly your liver and kidneys process the medication, affecting how long it stays active in your system. Additionally, variants in genes controlling appetite-regulating peptides—such as those in the MC4R and FTO pathways—interact with semaglutide's effects on your brain's satiety centers. PlexusDx maps 14 distinct peptide pathways to identify which genetic factors may help or hinder your response.
Clinical Evidence: What the Data Shows About Weight Loss Rates
Wegovy trials demonstrated that after 68 weeks, patients lost an average of 15% of body weight—but this average masks significant variation. Approximately 45% of participants achieved at least 15% weight loss, while 35% lost between 5% and 15%, and 20% lost less than 5%. This distribution reveals that semaglutide is not a one-size-fits-all solution. Factors like baseline weight, metabolic rate, adherence, and genetic makeup all influence where an individual falls within this range.
Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed higher average weight loss (up to 22% over 68 weeks) but displays the same individual variation pattern. The key insight is that genetics explains a meaningful portion of this variance. For example, people with the GLP1R rs6923761 variant show different dose-response patterns than those without it, suggesting that genetic screening could identify who benefits most from standard doses versus those needing personalized adjustment.
Genetic Factors That Predict Your Semaglutide Response
The Precision Peptide Genetic Test from PlexusDx analyzes 150+ genetic insights across 49 peptides and 14 metabolic pathways. Four key variants directly influence GLP-1 therapy outcomes: the GLP1R rs6923761 variant affects how strongly your GLP-1 receptors respond to semaglutide; the GIPR rs1800437 variant modulates GIP receptor function, relevant for dual-action therapies; the FTO rs9939609 variant influences appetite regulation and energy expenditure; and the MC4R rs17782313 variant controls melanocortin signaling in satiety pathways. Knowing your status at these loci helps predict whether you'll be a strong responder or may need dose optimization or medication switching.
Beyond these four primary variants, PlexusDx evaluates your genetic profile across metabolic, appetite-control, and hormone-signaling pathways. This comprehensive mapping identifies whether genetic factors favor rapid weight loss, whether you're at risk for gastrointestinal side effects based on gut-motility genes, and whether alternative compounds like tirzepatide might work better for your specific genetic makeup. This personalization happens after your first month of treatment, allowing PlexusDx to guide optimization decisions with real genetic data.
Lifestyle and Medication Factors That Influence Results
Even with perfect genetics for GLP-1 response, lifestyle choices remain critical. Consistent calorie deficit, adequate protein intake, regular physical activity, sleep quality, and stress management all enhance semaglutide's effects. Patients who combine medication with structured nutrition and exercise protocols typically exceed weight loss expectations, while those relying solely on the medication's appetite-suppressing effects often plateau. The medication removes the hunger barrier, but success still requires intentional behavior change.
Medication-specific factors also matter: dose consistency, injection timing, and adherence affect outcomes. Some people respond better to daily oral semaglutide than weekly injections due to pharmacokinetic differences; others show superior results with compounded formulations that allow dose flexibility. PlexusDx offers multiple delivery formats—injections starting at $149/mo, oral versions at $249/mo, and the microdose protocol at $129/mo—so you can match your treatment to your biology. Your dose may need to go up as your weight loss plateaus, but your price won't change, ensuring consistent access as your body responds.
How to Know If Semaglutide Is Working for You
Effective semaglutide response typically shows measurable changes within 4-8 weeks: reduced appetite, increased feelings of fullness, decreased food cravings, and steady weight loss of 1-2 pounds per week on average. If you experience none of these appetite changes after 6 weeks at your current dose, you may be a lower responder, which is not a failure—it's diagnostic information. Some people truly don't respond to GLP-1 monotherapy due to genetic factors affecting GLP1R sensitivity. In these cases, switching to tirzepatide (which targets both GIP and GLP-1 receptors) often produces results, since the dual-pathway approach bypasses GLP-1-specific resistance.
Track three metrics: appetite suppression (subjective but important), weight loss trajectory, and side-effect tolerance. If appetite suppression is strong but weight loss is slow, lifestyle factors or metabolic adaptation may be limiting results rather than the medication itself. If you experience severe nausea, vomiting, or constipation that doesn't resolve after 2-3 weeks, your GI-motility genetics may favor a lower dose or alternative compound. PlexusDx guides these decisions by reviewing your genetic data alongside your clinical response, enabling rapid optimization rather than prolonged trial-and-error.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What percentage of people don't lose weight on semaglutide?
Approximately 20% of semaglutide users lose less than 5% of body weight, though 'not losing weight' is rare; most experience some benefit. A larger percentage—around 35%—see modest results (5-15% loss) rather than the dramatic 15%+ loss others achieve. Genetics, lifestyle, and baseline metabolism all influence where you fall in this distribution. PlexusDx uses genetic testing to predict your likelihood of strong response and recommend personalization early.
Can genetic testing predict how well semaglutide will work for me?
Yes. The Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, MC4R, and 45 other peptide genes across 14 metabolic pathways, revealing your genetic predisposition to GLP-1 response. This test costs $99 as an add-on after your first month of treatment and helps PlexusDx recommend whether semaglutide, tirzepatide, or a dual-compound approach suits your biology best.
If I'm not responding to semaglutide, what are my options?
PlexusDx offers tirzepatide injection (starting at $249/mo) or the GLP-Squared dual-compound injection (starting at $249/mo), both of which target additional receptor pathways your body may respond to better. Your genetic test results guide this switch, reducing guesswork. All medications come from licensed 503A compounding pharmacies, are available across all 50 states, and have no membership fees or insurance requirements.
Is compounded semaglutide as effective as Wegovy?
Yes. Compounded semaglutide from licensed 503A pharmacies contains identical active ingredient and undergoes the same sterility and potency testing as brand Wegovy. The main difference is cost and flexibility: PlexusDx compounded semaglutide starts at $149/mo with no flat per-compound pricing increases, whereas Wegovy's brand price escalates with dose level. Efficacy data is equivalent; cost-effectiveness favors compounded options.
How does PlexusDx personalize GLP-1 therapy?
PlexusDx combines genetic testing with flexible dosing and multiple medication formats. After your first month on semaglutide injection ($149/mo), oral semaglutide ($249/mo), or the microdose protocol ($129/mo), you can opt for the Precision Peptide Genetic Test ($99) to reveal how your specific genes influence appetite, metabolism, and GLP-1 receptor function. This data guides optimization—dose increases, medication switches to tirzepatide, or shifts to dual-compound therapy—all at flat monthly prices without per-dose escalation.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
When Wegovy Start Working: Your Timeline for Sustainable Weight Loss Results
Why Do I Feel Hungry After Taking Ozempic?